Sickle Cell Disease Treatment Demonstration Program

0
164

Funding Opportunity ID:331673
Opportunity Number:HRSA-21-032
Opportunity Title:Sickle Cell Disease Treatment Demonstration Program
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Cooperative Agreement
Category of Funding Activity:Health
Category Explanation:https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=8d24c351-2384-4209-a572-19c0af5fbe62
CFDA Number(s):93.365
Eligible Applicants:Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility:Eligible applicants include a Federally-qualified health center, a nonprofit hospital or clinic, or a university health center that provides primary health care, that has a collaborative agreement with a community-based sickle cell disease organization or a nonprofit entity with experience in working with individuals who have sickle cell disease; and demonstrates to the HRSA Administrator that either the federally-qualified health center, the nonprofit hospital or clinic, the university health center, the organization or entity described in clause (i) 42 USC § 300b-5, or experts as described in paragraph (2)(C) of 42 USC § 300b-5, has at least five (5) years of experience in working with individuals who have sickle cell disease. Federally-qualified health center is defined in section 1905(l)(2)(B) of the Social Security Act (42 U.S.C. 1396d(l)(2)(B)).
Agency Code:HHS-HRSA
Agency Name:Department of Health and Human Services
Health Resources and Services Administration
Posted Date:Feb 23, 2021
Close Date:May 03, 2021
Last Updated Date:Feb 23, 2021
Award Ceiling:$0
Award Floor:$0
Estimated Total Program Funding:$5,000,000
Expected Number of Awards:5
Description:This notice announces the opportunity to apply for funding under the Sickle Cell Disease Treatment Demonstration Program (TDP). The purpose of the TDP is to increase access for individuals with sickle cell disease (SCD) to quality, coordinated, comprehensive care by: 1) increasing the number of clinicians or health professionals knowledgeable about the care of SCD, 2) improving the quality of care provided to individuals with SCD, and 3) improving care coordination with other providers.
Version:1





Visit the Official Webpage For More Details on Sickle Cell Disease Treatment Demonstration Program

LEAVE A REPLY

Please enter your comment!
Please enter your name here